1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Glutaminase

Glutaminase

Glutaminase is the initial enzyme in glutamine metabolism, which catalyzes the hydrolysis of glutamine to glutamate in cells. Glutaminase plays a key role in cancer cell metabolism, growth, and proliferation. In mammalian cells, there are two paralogous GLS genes, GLS1 (or GLS) and GLS2. GLS1 encodes two alternatively spliced isozymes: kidney glutaminase (KGA) and glutaminase C (GAC). GLS2 also encodes two isozymes: liver glutaminase (LGA) and glutaminase B.

GLS1 is ubiquitously expressed in various tissues, and its expression can be induced by the oncogene MYC. GLS1 is frequently activated and/or overexpressed in various types of cancer, including hepatocellular carcinoma (HCC). GLS1 has been reported to promote tumorigenesis in different types of cancer, including HCC, which is mainly attributable to its glutaminase activity and role in promoting glutamine metabolism. GLS has emerged as a critical enzyme in a number of cancer types. Elevated GLS2 enzymatic activity has also been correlated with tumor cell growth in vitro and in vivo. N-Myc activates GLS2 to promote conversion of glutamine to glutamate in MYCN-amplified neuroblastoma cells. Abrogation of GLS2 function profoundly inhibits glutaminolysis and dramatically decreases cell proliferation and survival in vitro and in vivo. However, there is controversy over the role of GLS2 as a tumor suppressor. Enzymatic activity independent of GLS2 is up-regulated via p53 or p63 and plays a role of tumor suppressor.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157975
    LM11
    Inhibitor
    LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state.
    LM11
  • HY-162141
    MD102
    Inhibitor
    MD102 is a potent TG2 inhibitor with an IC50 value of 0.35 μM. MD102 stabilizes p53 by inhibiting TG2, inducing a decrease in p-AKT and p-mTOR downstream signaling, leading to tumor cell apoptosis.
    MD102
  • HY-146617
    GLS1 Inhibitor-4
    Inhibitor
    GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity.
    GLS1 Inhibitor-4
  • HY-152207
    LWG-301
    Inhibitor
    LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC50 value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model.
    LWG-301
  • HY-157254
    AA10
    Inhibitor
    AA10 is a potent and irreversible transglutaminase 2 (TG2) inhibitor for cancer research.
    AA10
  • HY-149602
    Glutaminase C-IN-2
    Inhibitor
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects.
    Glutaminase C-IN-2
  • HY-148241
    A-446
    Inhibitor
    A-446 is a potent glutaminase (GLS) inhibitor with an IC50 value of 31 nM.
    A-446
  • HY-129126
    NC9
    Inhibitor
    NC9 (Cbz-Lys(Acr)-PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation.
    NC9
  • HY-155643
    PROTAC TG2 degrader-1
    Inhibitor
    PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a KD of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner.
    PROTAC TG2 degrader-1
  • HY-N2916
    Barbinervic acid
    Inhibitor
    Barbinervic acid is a glutaminase inhibitor with an IC50 of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases.
    Barbinervic acid
  • HY-W020050S
    Cystamine-d8 dihydrochloride
    Cystamine-d8 (dihydrochloride) is the deuterium labeled Cystamine (dihydrochloride)[1]. Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD)[2][3][4].
    Cystamine-d<sub>8</sub> dihydrochloride
  • HY-W015309R
    Decanoic acid (Standard)
    Inhibitor
    Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.
    Decanoic acid (Standard)
  • HY-105723
    Duazomycin
    Antagonist
    Duazomycin A is a glutamine antagonist. Duazomycin A can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) (HY-13677) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.
    Duazomycin
  • HY-114929
    THDP17
    Inhibitor
    THDP17 is an orally active glutaminase inhibitor. THDP17 decreases ammonia production through glutaminase inhibition.
    THDP17
Cat. No. Product Name / Synonyms Application Reactivity